Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

NCT06206421 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT06206421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06206421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
February 22, 2024
Completion date
March 19, 2026
Enrollment
277 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes